Short Interest in Gyrodyne , LLC (NASDAQ:GYRO) Decreases By 74.4%

Posted by Tyrone Williams on Feb 26th, 2026

Gyrodyne , LLC (NASDAQ:GYRO – Get Free Report) was the recipient of a large drop in short interest in February. As of February 13th, there was short interest totaling 52 shares, a drop of 74.4% from the January 29th total of 203 shares. Based on an average daily volume of 472 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the shares of the stock are sold short. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily volume of 472 shares, the short-interest ratio is currently 0.1 days.

Gyrodyne Price Performance

Gyrodyne stock opened at $8.88 on Thursday. Gyrodyne has a fifty-two week low of $6.80 and a fifty-two week high of $12.00. The stock’s fifty day moving average is $8.94 and its two-hundred day moving average is $9.61.

Institutional Investors Weigh In On Gyrodyne

A number of large investors have recently added to or reduced their stakes in the business. Bulldog Investors LLP acquired a new position in Gyrodyne during the third quarter worth about $601,000. Teton Advisors LLC acquired a new stake in shares of Gyrodyne in the third quarter valued at approximately $177,000. Susquehanna International Group LLP purchased a new position in shares of Gyrodyne during the 3rd quarter worth approximately $142,000. Finally, Advisory Services Network LLC acquired a new position in shares of Gyrodyne during the 3rd quarter worth approximately $77,000. 71.36% of the stock is owned by institutional investors and hedge funds.

About Gyrodyne

(Get Free Report)

Gyrodyne Company of America, Inc is a New York–based real estate investment and development firm specializing in medical office buildings and professional facilities. Listed on the NASDAQ under the ticker GYRO, the company’s principal business activity is the ownership, leasing and management of commercial properties tailored to healthcare and life sciences tenants. By focusing on outpatient diagnostic and treatment centers, clinical laboratories and related professional suites, Gyrodyne generates steady rental income and seeks to provide purpose-built environments that meet the specific needs of medical practitioners and research organizations.

The company’s core property portfolio is anchored by an approximately 87-acre campus situated in Stony Brook, Long Island.